“…By compiling the results of WES, targeted resequencing (Figure 2A), and high-resolution SNP array analysis ( Figure 2B), 41 genes were recurrently affected in $3 of 35 (9%) of NMZL by mutations (n 5 32 genes) or focal CNA (n 5 9 genes), including MLL2 (also known as KMT2D, 34%), PTPRD (20%), NOTCH2 (20%), and KLF2 (17%) ( Figure 3A; supplemental Tables 3 and 4 . Prevalence of nonsynonymous PTPRD mutations among mature B-cell tumors (NMZL, nodal marginal zone lymphoma, data from this study; SMZL, splenic marginal zone lymphoma, data from this study and others 5,6,7,9 ; DLBCL, diffuse large B-cell lymphoma, data from various studies 22,37,45,47 ; BL, Burkitt lymphoma, data from various studies 40,41 ; CLL, chronic lymphocytic leukemia, data from various studies 38,39,44,49 ; MCL, mantle cell lymphoma, data from Beà et al 43 ; PMBCL, primary mediastinal large B-cell lymphoma, data from Gunawardana et al 15 ; FL, follicular lymphoma, data from various studies 37,48 ; MM, multiple myeloma, data from Chapman et al 36 ; WM, Waldenström macroglobulinemia, data from various studies 42,46 ; EMZL, extranodal marginal zone lymphoma, data from this study; PCNSL primary central nervous system lymphoma, data from various studies [52][53][54][55] ).…”